Bharat Biotech inks pact with WU's School of Medicine for COVID-19 intranasal vaccine
According to a press release issued by the city-based vaccine maker,
Bharat Biotech owns the rights to distribute the vaccine in all
markets except the US, Japan and Europe. While the Phase I trials will
take place in St Louis University's Vaccine and Treatment Evaluation
Unit, Bharat Biotech, upon obtaining the required regulatory approval,
will pursue further stages of clinical trials in India.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-inks-pact-with-wus-school-of-medicine-for-covid-19-intranasal-vaccine/articleshow/78269826.cms
Bharat Biotech owns the rights to distribute the vaccine in all
markets except the US, Japan and Europe. While the Phase I trials will
take place in St Louis University's Vaccine and Treatment Evaluation
Unit, Bharat Biotech, upon obtaining the required regulatory approval,
will pursue further stages of clinical trials in India.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-inks-pact-with-wus-school-of-medicine-for-covid-19-intranasal-vaccine/articleshow/78269826.cms
Comments
Post a Comment